---
layout: default
title: Dorzolamide
description: "Dorzolamide 的老藥新用潛力分析。中等證據等級 L3，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 62
evidence_level: L1
indication_count: 10
---

# Dorzolamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dorzolamide：從高眼壓症到原發性遺傳性青光眼

## 一句話總結

<p class="key-answer" data-question="Dorzolamide 可以用於治療什麼新適應症？">
Dorzolamide 原本用於治療高眼壓症及廣角性青光眼。
TxGNN 模型預測它可能對**原發性遺傳性青光眼 (primary hereditary glaucoma)** 有效，
目前有 **1 個臨床試驗**和多項開角性青光眼研究支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 高眼壓症、廣角性青光眼 |
| 預測新適應症 | open-angle glaucoma、primary hereditary glaucoma、hypotrichosis simplex of the scalp、congenital hypotrichosis milia、alopecia、diffuse alopecia areata、glaucoma 1, open angle、open angle glaucoma、congestive heart failure、acute pulmonary heart disease |
| TxGNN 預測分數 | 99.99% |
| 證據等級 | L3 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed with Guardrails |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. primary hereditary glaucoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>Dorzolamide 是碳酸酐酶抑制劑，透過抑制眼內睫狀體的碳酸酐酶 II 型，</p>
<p>減少房水分泌，從而降低眼內壓。其在開角性青光眼中的療效已被證實，</p>
<p>而原發性遺傳性青光眼雖然病因涉及基因突變，但眼壓升高仍是主要致病機轉，</p>
<p>因此降眼壓治療在機轉上具有合理性。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr>
<th>試驗編號</th>
<th>階段</th>
<th>狀態</th>
<th>人數</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01527682">NCT01527682</a></td>
<td>Phase 2</td>
<td>COMPLETED</td>
<td>37</td>
<td>評估 latanoprost 和 dorzolamide 在兒童先天性青光眼的降眼壓效果</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00333125">NCT00333125</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>319</td>
<td>比較兩種複方製劑在開角性青光眼的療效</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00108017">NCT00108017</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>330</td>
<td>評估 dorzolamide/timolol 複方的 24 小時降眼壓效果</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00991822">NCT00991822</a></td>
<td>Phase 2/3</td>
<td>COMPLETED</td>
<td>160</td>
<td>比較 dorzolamide 和 timolol 對視神經盤血流的影響</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02325518">NCT02325518</a></td>
<td>Phase 4</td>
<td>COMPLETED</td>
<td>218</td>
<td>比較 brinzolamide/timolol 與 dorzolamide/timolol 複方的療效</td>
</tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>年份</th>
<th>類型</th>
<th>期刊</th>
<th>主要發現</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26526633/">26526633</a></td>
<td>2016</td>
<td>Meta-analysis</td>
<td>Ophthalmology</td>
<td>系統性回顧比較開角性青光眼一線藥物治療的療效</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39569785/">39569785</a></td>
<td>2024</td>
<td>Clinical study</td>
<td>Vestnik oftalmologii</td>
<td>評估 dorzolamide/timolol 複方在開角性青光眼的療效和安全性</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/37425383/">37425383</a></td>
<td>2023</td>
<td>Clinical study</td>
<td>MJMS</td>
<td>比較固定複方與非固定複方 dorzolamide/timolol 的療效和依從性</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39677168/">39677168</a></td>
<td>2024</td>
<td>RCT</td>
<td>Cureus</td>
<td>比較 brinzolamide/timolol 與 dorzolamide/timolol 複方在印度患者的療效</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. alopecia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15091328/" target="_blank">15091328</a></td><td>2004</td><td>Article</td><td>Veterinary ophthalmo</td><td>Uveodermatologic syndrome in a Brazilian Fila dog.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. glaucoma 1, open angle</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.75%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（41 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00333125" target="_blank">NCT00333125</a></td><td>PHASE3</td><td>COMPLETED</td><td>319</td><td>A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01887223" target="_blank">NCT01887223</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Tre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01896180" target="_blank">NCT01896180</a></td><td>PHASE2</td><td>COMPLETED</td><td>63</td><td>A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Lat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00314171" target="_blank">NCT00314171</a></td><td>PHASE3</td><td>COMPLETED</td><td>437</td><td>A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertensio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822081" target="_blank">NCT00822081</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
</tbody>
</table>
<p><em>...及其他 36 項試驗</em></p>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26526633/" target="_blank">26526633</a></td><td>2016</td><td>Article</td><td>Ophthalmology</td><td>Comparative Effectiveness of First-Line Medications for Prim...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39569785/" target="_blank">39569785</a></td><td>2024</td><td>Article</td><td>Vestnik oftalmologii</td><td>[Efficacy and safety of the fixed combination of dorzolamide...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37425383/" target="_blank">37425383</a></td><td>2023</td><td>Article</td><td>The Malaysian journa</td><td>Comparing the Effectiveness and Adherence between Fixed and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39677168/" target="_blank">39677168</a></td><td>2024</td><td>Article</td><td>Cureus</td><td>Efficacy and Safety of a Fixed-Dose Combination of Brinzolam...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34447609/" target="_blank">34447609</a></td><td>2021</td><td>Article</td><td>Journal of drug asse</td><td>Efficacy and safety of timolol-dorzolamide fixed-combination...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. open angle glaucoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.70%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00333125" target="_blank">NCT00333125</a></td><td>PHASE3</td><td>COMPLETED</td><td>319</td><td>A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01887223" target="_blank">NCT01887223</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Tre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01896180" target="_blank">NCT01896180</a></td><td>PHASE2</td><td>COMPLETED</td><td>63</td><td>A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Lat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00314171" target="_blank">NCT00314171</a></td><td>PHASE3</td><td>COMPLETED</td><td>437</td><td>A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertensio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00822081" target="_blank">NCT00822081</a></td><td>PHASE4</td><td>COMPLETED</td><td>140</td><td>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timo...</td></tr>
</tbody>
</table>
<p><em>...及其他 45 項試驗</em></p>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26526633/" target="_blank">26526633</a></td><td>2016</td><td>Article</td><td>Ophthalmology</td><td>Comparative Effectiveness of First-Line Medications for Prim...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38985892/" target="_blank">38985892</a></td><td>2024</td><td>Article</td><td>Journal of cataract </td><td>Open-angle glaucoma and Fuchs dystrophy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39569785/" target="_blank">39569785</a></td><td>2024</td><td>Article</td><td>Vestnik oftalmologii</td><td>[Efficacy and safety of the fixed combination of dorzolamide...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40261315/" target="_blank">40261315</a></td><td>2025</td><td>Article</td><td>The Medical letter o</td><td>Drugs for open-angle glaucoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37425383/" target="_blank">37425383</a></td><td>2023</td><td>Article</td><td>The Malaysian journa</td><td>Comparing the Effectiveness and Adherence between Fixed and ...</td></tr>
</tbody>
</table>
<p><em>...及其他 15 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. congestive heart failure</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.61%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（2 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38450431/" target="_blank">38450431</a></td><td>2024</td><td>Article</td><td>Expert opinion on dr</td><td>Drug interactions of carbonic anhydrase inhibitors and activ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14620034/" target="_blank">14620034</a></td><td>2003</td><td>Article</td><td>Canadian journal of </td><td>Prescription of topical antiglaucoma agents for patients wit...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. respiratory failure</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16879567/" target="_blank">16879567</a></td><td>2006</td><td>Article</td><td>Acta ophthalmologica</td><td>Optic nerve pH and PO2: the effects of carbonic anhydrase in...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 多張許可證 | 鹽酸多佐胺 | 眼用製劑 | 高眼壓症、廣角性青光眼、開放性青光眼 |

## 安全性考量

- **常見不良反應**：眼部刺痛、苦味、結膜充血
- **禁忌症**：對磺胺類藥物過敏者
- **藥物交互作用**：與其他碳酸酐酶抑制劑併用時需注意累加效應

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
Dorzolamide 的降眼壓機轉在遺傳性青光眼中仍然適用，已有一項兒童先天性青光眼的臨床試驗，
但遺傳性青光眼的特殊性需要更多針對性研究。

**若要推進需要：**
- 針對不同基因突變類型的療效分層研究
- 兒童青光眼長期安全性數據
- 與其他降眼壓藥物的組合治療方案優化


---

## 相關藥物報告

- [Ribavirin]({{ "/drugs/ribavirin/" | relative_url }}) - 證據等級 L3
- [Prednisolone]({{ "/drugs/prednisolone/" | relative_url }}) - 證據等級 L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - 證據等級 L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - 證據等級 L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Dorzolamide老藥新用驗證報告. https://twtxgnn.yao.care/drugs/dorzolamide/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_dorzolamide,
  title = {Dorzolamide老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dorzolamide/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
